Mironid
Mironid59About
What does Mironid do?
Mironid is a biopharmaceutical company focused on developing first-in-class LoAc small molecule drug candidates that directly target the central signaling mechanism driving Autosomal Dominant Polycystic Kidney Disease (ADPKD). Their lead candidate, MR-L45, aims to reduce cyst formation and growth by activating long-form PDE4 enzymes, increasing the breakdown of cAMP, and offering a differentiated treatment option for patients with limited alternatives.
What is Mironid's Effective Domain Rating?
StartupHub's Effective Domain Rating for Mironid is 62 out of 100, measuring real cross-surface visibility in search engines and AI answers rather than claimed link authority. That is underrated against its Ahrefs Domain Rating of 12, meaning it surfaces in search and AI results more than its claimed authority alone would suggest.
Is Mironid trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Mironid is 61 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
What is Mironid's revenue?
StartupHub estimates Mironid's annual revenue at $2.0M (range $1.1M to $5.7M, 68% confidence), based on comparable companies in the sector.
What is Mironid's valuation?
StartupHub estimates Mironid's effective valuation at $192.3M (range $115.0M to $276.0M, 24% confidence), based on comparable companies in the sector.
How much funding has Mironid raised?
Mironid has raised a total of $46M in funding. The most recent round on record is Series B.
Where is Mironid headquartered?
Mironid is headquartered in Glasgow, United Kingdom.
When was Mironid founded?
Mironid was founded in 2015.
What industry does Mironid operate in?
Mironid operates in Biotechnology, Pharmaceuticals, Drug Discovery, Medical Devices, Healthcare, Biotech.
How many employees does Mironid have?
Mironid has approximately 16 people on record.
No comments yet. Be the first to share your take.